Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Systematic review of statins in sepsis: There is no evidence of dose response.

Quinn M, Moody C, Tunnicliffe B, Khan Z, Manji M, Gudibande S, Murphy N, Whitehouse T, Snelson C, Veenith T.

Indian J Crit Care Med. 2016 Sep;20(9):534-41. doi: 10.4103/0972-5229.190366.

2.

Statins and its hepatic effects: Newer data, implications, and changing recommendations.

Jose J.

J Pharm Bioallied Sci. 2016 Jan-Mar;8(1):23-8. doi: 10.4103/0975-7406.171699. Review.

3.

Effects of policosanol on borderline to mildly elevated serum total cholesterol levels: a prospective, double-blind, placebo-controlled, parallel-group, comparative study.

Castaño G, Más R, Fernández J, López E, Illnait J, Fernández L, Mesa M.

Curr Ther Res Clin Exp. 2003 Sep;64(8):522-37. doi: 10.1016/j.curtheres.2003.09.002.

4.

Protective Effects of N-acetylcysteine Against the Statins Cytotoxicity in Freshly Isolated Rat Hepatocytes.

Abdoli N, Azarmi Y, Eghbal MA.

Adv Pharm Bull. 2014;4(3):249-54. doi: 10.5681/apb.2014.036. Epub 2014 Feb 7.

5.

Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory.

Stuart SA, Robertson JD, Marrion NV, Robinson ES.

PLoS One. 2013 Sep 10;8(9):e75467. doi: 10.1371/journal.pone.0075467. eCollection 2013.

6.

The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention.

Zacharski LR, DePalma RG, Shamayeva G, Chow BK.

Am J Public Health. 2013 Apr;103(4):e105-12. doi: 10.2105/AJPH.2012.301163. Epub 2013 Feb 14. Erratum in: Am J Public Health. 2013 May;103(5):e9.

7.
8.
9.

Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.

Simpson RJ Jr, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.

Mayo Clin Proc. 2009 Dec;84(12):1065-72. doi: 10.4065/mcp.2009.0298.

10.

Optimal lipid modification: the rationale for combination therapy.

Backes JM, Gibson CA, Howard PA.

Vasc Health Risk Manag. 2005;1(4):317-31. Review.

11.

Statins research unfinished saga: desirability versus feasibility.

Fisman EZ, Adler Y, Tenenbaum A.

Cardiovasc Diabetol. 2005 Jun 7;4:8.

12.

Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.

Zhou Z, Rahme E, Abrahamowicz M, Tu JV, Eisenberg MJ, Humphries K, Austin PC, Pilote L.

CMAJ. 2005 Apr 26;172(9):1187-94.

13.

Inhibition of pancreatic cholesterol esterase reduces cholesterol absorption in the hamster.

Heidrich JE, Contos LM, Hunsaker LA, Deck LM, Vander Jagt DL.

BMC Pharmacol. 2004 Apr 19;4:5.

14.

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, Sugiyama Y.

Br J Pharmacol. 2003 Jul;139(5):911-8.

15.

Interaction of common azole antifungals with P glycoprotein.

Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW.

Antimicrob Agents Chemother. 2002 Jan;46(1):160-5.

16.

Drug interactions and the statins.

Herman RJ.

CMAJ. 1999 Nov 16;161(10):1281-6. Review.

17.

Post-transplant hyperlipidaemia.

Jindal RM.

Postgrad Med J. 1997 Dec;73(866):785-93. Review.

Supplemental Content

Support Center